1958

Founder of the company Dr. Saad El Bardissi, during the inauguration ceremony of the first privately owned pharmaceutical company partnering with world leaders in the industry.

1960

Heliopolis Pharmaceutical laboratories, signed the first under-licence agreement with Philips-Duphar.

1960's

Pharmaceutical Production of standard and sterile products, in Heliopolis Pharmaceutical factory.

1960's

Development and quality control.

1960's

Development and quality control.

1960's

The economy and industry experienced turbulent times in the history of Egypt, starting from the sixties, merger and nationalization has led to a temporary halt of the production activity.

1992

Start of operation of MINAPHARM and building of MINAPHARM factory.

1992

The ideal link to the pharmaceutical world.
MINAPHARM is re-established as a multi-alliance company with worldwide links to the pharmaceutical industry.

1998

MINAPHARM differentiates its portfolio into a specialty pharmaceutical company with dedicated lines in gastroenterology, cardiology, orthopedics and uro-gynaecology.

2001

First Joint Venture in Biotechnology in emerging markets:
MINAPHARM enters into a joint-venture with Rhein-Biotech in Germany to establish the first Biotech firm in Egypt, Africa and the Middle-East.

2003

Operation of
Rhein-Minapharm uniquely dedicated to the development and manufacturing of therapeutic proteins, using different eukaryotic expression systems (yeast and mammalian cell culture).

2005

Launch of Reiferon 3&6 MIU (IFN-α2a); the first product produced by recombinant DNA technology, followed by the first pegylated Interferon; Reiferon Retard, in 2006 and start of the R & D department.

2005

Launch of Reiferon 3&6 MIU (IFN-α2a); the first product produced by recombinant DNA technology, followed by the first pegylated Interferon; Reiferon Retard, in 2006 and start of the R & D department.

2008

Launch of the world first's topically applied recombinant protein brands:Extrauma and Thrombexx, as well as one of two parenteral forms available worldwide for the treatment of serious thrombotic complications.

2008

Launch the world first's topically applied recombinant protein brands:Extrauma and Thrombexx, as well as one of two parentral forms available worlwide for the treatment of serious thrombotic complications.

2008

Launch the world first's topically applied recombinant protein brands:Extrauma and Thrombexx, as well as one of two parentral forms available worlwide for the treatment of serious thrombotic complications.

2009

Expansion of the sterile pharmaceutical area as the-state-of-the-art and the most advanced sterile area in Egypt and the Middle East.

2009

Expansion of the pharmaceutical sterile area as the-state-of-the-art and the most advanced sterile area in Egypt and the Middle East.

2010

Acquisition of ProBioGen: The Berlin-based market leader in cell-line Engineering in Europe.

2014

Start of operation of the first Egyptian-Middle Eastern mammalian cell production using genetic engineering. MINAPHARM is launching the first mammalian-derived product Gonapure, recombinant human FSH.